中文名 | WAY-262611 |
英文名 | WAY-262611 |
别名 | WAY-262611游离态 Β-联蛋白激动剂(WAY-262611) 1-[4-(2-萘基)-2-嘧啶基]-4-哌啶甲胺 (1-(4-(萘-2-基)嘧啶-2-基)哌啶-4-基)甲胺 |
英文别名 | DKK1 MAY-262611 WAY-262611 1-[4-(2-Naphthalenyl)-2-pyrimidinyl]-4-piperidinemethanamine 1-{1-[4-(2-Naphthyl)-2-pyrimidinyl]-4-piperidinyl}methanamine 4-PiperidineMethanaMine, 1-[4-(2-naphthalenyl)-2-pyriMidinyl]- 1-[4-(2-Naphthalenyl)-2-pyrimidinyl]-4-piperidinemethanamine MAY-262611 |
CAS | 1123231-07-1 |
EINECS | 604-604-1 |
化学式 | C20H22N4 |
分子量 | 318.42 |
密度 | 1.169±0.06 g/cm3(Predicted) |
沸点 | 544.8±42.0 °C(Predicted) |
溶解度 | DMSO: ≥ 42 mg/mL |
酸度系数 | 10.13±0.29(Predicted) |
存储条件 | under inert gas (nitrogen or Argon) at 2–8 °C |
体外研究 | WAY-262611 has the most potent activity in the primary assay, low kinase inhibition potential, and high solubility. |
体内研究 | WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wnt β -catenin pathway and most likely through inhibition of Dkk-1. |
上游原料 | 2-氯-4-(萘-2-基)嘧啶 4-氨甲基哌啶 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.141 ml | 15.703 ml | 31.406 ml |
5 mM | 0.628 ml | 3.141 ml | 6.281 ml |
10 mM | 0.314 ml | 1.57 ml | 3.141 ml |
5 mM | 0.063 ml | 0.314 ml | 0.628 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!